23 results on '"Pérez-Moreno, Pablo"'
Search Results
2. Neoadjuvant palbociclib plus either giredestrant or anastrozole in oestrogen receptor-positive, HER2-negative, early breast cancer (coopERA Breast Cancer): an open-label, randomised, controlled, phase 2 study
3. Giredestrant for Estrogen Receptor–Positive, HER2-Negative, Previously Treated Advanced Breast Cancer: Results From the Randomized, Phase II acelERA Breast Cancer Study.
4. LINC00662 Promotes Aggressive Traits by Modulating OCT4 Expression through miR-335-5p in Gallbladder Cancer Cells.
5. The CK2/ECE1c Partnership: An Unveiled Pathway to Aggressiveness in Cancer
6. The CK2/ECE1c Partnership: An Unveiled Pathway to Aggressiveness in Cancer.
7. The Role of MicroRNAs in Breast Cancer and the Challenges of Their Clinical Application
8. Long Non-Coding RNAs (lncRNAs) as Regulators of the PI3K/AKT/mTOR Pathway in Gastric Carcinoma
9. A Single Variant in Pri-miRNA-155 Associated with Susceptibility to Hereditary Breast Cancer Promotes Aggressiveness in Breast Cancer Cells
10. Neoadjuvant giredestrant (GDC-9545) plus palbociclib (P) versus anastrozole (A) plus P in postmenopausal women with estrogen receptor–positive, HER2-negative, untreated early breast cancer (ER+/HER2– eBC): Final analysis of the randomized, open-label, international phase 2 coopERA BC study.
11. Describing U.S. real-world patients (pts) with hormone receptor-positive early breast cancer (HR+ EBC) by risk status.
12. Environmental and Lifestyle Risk Factors in the Carcinogenesis of Gallbladder Cancer
13. The Emerging Role of PIWI-Interacting RNAs (piRNAs) in Gastrointestinal Cancers: An Updated Perspective
14. Role of lncRNAs in the Development of an Aggressive Phenotype in Gallbladder Cancer
15. Phosphorylation of Endothelin-Converting Enzyme-1c at Serines 18 and 20 by CK2 Promotes Aggressiveness Traits in Colorectal Cancer Cells
16. Endothelin‐converting enzyme‐1c promotes stem cell traits and aggressiveness in colorectal cancer cells
17. Endothelin‐converting enzyme‐1c promotes stem cell traits and aggressiveness in colorectal cancer cells.
18. Establecimiento de un plan de mejora para nuevas variedades de melón piel de sapo (Cucumis Melo l.)
19. Establecimiento de un plan de mejora para nuevas variedades de melón piel de sapo (Cucumis Melo l.)
20. lidERA Breast Cancer (BC): Phase III adjuvant study of giredestrant vs. physician's choice of endocrine therapy (PCET) in patients (pts) with estrogen receptor-positive, HER2-negative early BC (ER+, HER2– eBC).
21. Endocrine therapy resistance (ETR) in hormone receptor-positive, HER2-negative metastatic breast cancer (HR+, HER2– mBC): Prevalence, biomarker characteristics, and outcomes.
22. Exploratory biomarker analysis of acelERA breast cancer (BC): Phase II study of giredestrant vs. physician's choice of endocrine therapy (PCET) for previously treated, estrogen receptor-positive, HER2-negative advanced BC (ER+, HER2– aBC).
23. The Emerging Role of PIWI-Interacting RNAs (piRNAs) in Gastrointestinal Cancers: An Updated Perspective.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.